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Abstract (200 words) 
Background:  The properties required of an intervention that results in eradication or control 
of HIV in absence of antiretroviral therapy (ART-free viral suppression) to make it cost-
effective in low income settings are unknown. 
Methods: We used a model of HIV and ART to investigate the effect of introducing an ART-
free viral suppression intervention in 2022 in an example country of Zimbabwe.  We assumed 
that the intervention (cost: $500) would be accessible for 90% of the population, be given to 
those on effective ART, have sufficient efficacy to allow ART interruption in 95%, with a 
rate of viral rebound 5% per year in the first three months, and a 50% decline in rate with 
each successive year.  
Results: An ART-free viral suppression intervention with these properties would result in 
over 0.53 million disability-adjusted-life-years averted over 2022-2042, with a reduction in 
HIV programme costs of $300 million (8.7% saving).  An intervention of this efficacy 
costing anything up to $1400 is likely to be cost-effective in this setting.   
Conclusion: Interventions aimed at curing HIV have the potential to improve overall disease 
burden and to reduce costs.  Given the effectiveness and cost of ART, such interventions 
would have to be inexpensive and highly effective.   
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Introduction   
 
Research is on-going into developing an intervention which would allow HIV positive 
individuals to have prolonged, and perhaps permanent, viral suppression in the absence of 
therapy (“remission”, “cure”). We refer to this as antiretroviral therapy-free viral suppression 
(1-8). The implications of this research for sub-Saharan Africa, where most people with HIV 
live, are as yet unclear, and any such intervention requires consideration in the context of 
resource-constrained public health approaches to treatment and prevention.  Knowing what 
properties are likely to be required of such an intervention in order for it to be cost effective, 
or cost saving in low income, high HIV prevalence settings (i.e. a “target product profile”) is 
important in order to focus research, clinical development and delivery approaches. Here, we 
sought to identify some basic product and delivery attributes within a framework of a global 
policy agenda.  We address the following research questions. First, what would be the 
predicted impact of an intervention to induce sustained ART-free HIV suppression in low 
income countries in sub-Saharan Africa, in terms of death rates, HIV incidence, and 
disability-adjusted life years (DALYs)? Secondly, under what conditions, particularly those 
relating to efficacy and cost, would such an intervention represent a cost-effective approach, 
within the context of continued expansion in access to ART?  
 
Methods 
Model and Context 
We assess these questions in the context of a generalised HIV epidemic with on-going ART 
roll-out using a model that has been informed by, and calibrated to, data from Zimbabwe (9-
19).  We used the HIV Synthesis transmission model, an individual-based stochastic model of 
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heterosexual HIV transmission, progression and treatment in adults that has been previously 
described (20-23; and see Supplementary Material).  Each simulation run generates time-
updated longitudinal “data” over time for a population of people from 1989 such that the 
overall characteristics of the population in terms of age, gender, sexual risk behaviour and 
HIV status resembles that of the entire adult population of Zimbabwe (HIV positive and 
negative).  Transmission of HIV is modelled, with the HIV status of each (condomless sex) 
partner being sampled, along with viral load status of HIV positive partners. For people who 
have become infected with HIV the variables for which longitudinal data are simulated 
include viral load, CD4 count, presence of resistance mutations, whether they have tested 
HIV positive, whether they are linked to care, whether they are maintained in care and on 
treatment, and occurrence of AIDS and death.  
  
Evaluation of the impact of an ART-free viral suppression intervention depends on the 
predicted outcomes in the absence of such an intervention and, in particular, the projected 
long term effects of ART. The first-line regimen is assumed to be composed of 
efavirenz/lamivudine/tenofovir and the second line regimen ritonavir-boosted 
atazanavir/zidovudine/lamivudine. It is assumed that no third line will be available. Table 1 
presents the modelled 10 and 20 year outcomes after the start of ART.  These outputs reflect 
model assumptions regarding adherence patterns, resistance acquisition, effect of adherence 
and resistance on virologic outcome and CD4 count changes, the rate of interruption of ART 
and of ART toxicity, as detailed elsewhere (Supplementary Material; 24-29).  
 
We initially concentrate on a base case analysis and then consider a number of sensitivity 
analyses (Supplementary Table 1).  We assumed that rates of HIV testing and hence ART 
coverage will continue to rise, although by lower amounts than has been the case in the last 
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five years and that the policy will be for ART initiation in people with CD4 count <500 
cells/mm
3
 and option B+ for pregnant women from 2015. Viral load monitoring of people on 
ART is assumed to start from 2015 onwards.   We also assume a modest increase in levels of 
condomless sex such that HIV incidence is projected to decline only modestly (Figure 1).  
We assume continuation of trends in male circumcision uptake and no introduction of pre-
exposure prophylaxis.  
 
ART-Free Viral Suppression Intervention  
We envisaged an intervention that would induce ART-free viral suppression either by 
activating and killing latently infected cells and thus depleting the reservoir to zero or close to 
zero or by enhancing long-term immune control of a durable reservoir, with or without 
reservoir reduction.  We assume the intervention is introduced in 2022 and that 90% of 
people in the country would have access to the intervention should they fulfil the eligibility 
criteria (50% in sensitivity analysis, perhaps more realistic if the intervention requires intra-
venous administration). We assume that the eligibility criteria for the intervention is an 
undetectable viral load  for at least 6 months and a CD4 cell count over 500 cells/mm
3
.   We 
consider that a cure intervention would be most likely to be started in people in whom ART 
had initially been used in order to reduce replicating virus.   We assume that the ART-free 
viral suppression intervention would be administered for six months (while ART is 
continued).   
 
We assume that 95% of those given the ART-free viral suppression intervention will be 
adjudged to have had a sufficient response to be able to stop ART. We then assume that 
failure—defined as a rebound in viremia--will occur initially at a rate of 0.05 per year in the 
first 3 months (e.g. the probability of rebound is 0.05/4 in the first 3 month period), which 
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declines thereafter by 50% per year (so, for example, the probability of rebound in the second 
3 month period is 0.05 x 0.5
0.25
; this equates to ~ 8% of people having viral rebound by 5 
years after interruption of ART).   Viral load and CD4+ T cell count dynamics during ART-
free viral suppression failure were assumed to be comparable to that of an ART interruption.  
During periods of ART-free viral suppression, we assume that the CD4 count will continue to 
improve, as is the case with continued viral suppression on ART. We also assume that CD4 
count- and age-specific morbidity and mortality will be no different to that in people on ART 
with viral suppression; i.e. including that there remains some residual excess risk over and 
above that in the uninfected population (1.3-fold assumed; 1.0- and 1.7-fold considered in 
sensitivity analysis) (30-32). We also consider in sensitivity analysis that the excess risk is 
1.3-fold (and, in a further sensitivity analysis that it is 1.7 fold) for people on ART with viral 
suppression and 1.0-fold for those with ART-free viral suppression.  
 
We assume that individuals who have received the ART-free viral suppression intervention 
will be monitored with viral load tests every 3 months for the first 5 years after ART 
interruption, and annually thereafter (as opposed to the annual monitoring throughout for 
people on ART). This is to try to ensure rapid identification of viral rebound if it occurs.  We 
further assume that individuals with ongoing ART-free viral suppression are susceptible to 
super-infection, which will lead to viral rebound, while people on ART are assumed to not 
have risk of super-infection, due to the protective effects of ART. 
  
Consequences of disengaging from care are different for people on ART and those with 
ART-free viral suppression.  For those on ART, adherence to regular care / drug pick-up is 
essential for continued viral suppression. In contrast, for those who have successfully 
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achieved ART-free viral suppression, disengagement from care does not have negative 
consequences unless and until viral load rebound occurs  
 
Those on ART with viral rebound will be eligible to be switched to second line - the rate of 
switch in such circumstances is 20% per 3 months once the above failure criteria are met. 
People are assumed to be given a maximum of one round of the ART-free viral suppression 
intervention.  
 
Main Outcomes and Economic analysis 
 
The time perspective of the analysis was 20 years (2022-2042). The main outcome is 
disability adjusted life years (DALYs) for individuals between ages of 15 and 65 years. The 
DALY is a measure of overall disease burden. A person incurs a fraction of a DALY for each 
period of time lived with a disability, and a whole DALY for each year in which they have 
died but would still be under age 65 had they lived. Only HIV or ART related disability is 
considered. The analysis was from a health systems perspective. We consider DALYs and 
costs in the whole population, not just those with HIV, so that effects of transmission are 
accounted for.  
 
A one-off cost of the ART-free viral suppression intervention of $500 ($200 and $2000 in 
sensitivity analyses) is assumed (including cost of viral load testing in the time before, and 
the first few weeks after, ART interruption). The cost of clinic visits during ART-free viral 
suppression success is assumed to be $10 per 3 months ($5 in a sensitivity analysis), 
compared with $20 for people on ART (33), the cost assumed lower as the person is not on 
ART. The current annual cost (including supply chain) of the first-line regimen is assumed to 
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be $144 per person per year, and the second-line regimen is assumed to cost $312 per person 
per year (34).   
 
The degree of disability experienced by a person – which is relevant in calculation of DALYs 
- is measured on a scale of 0 – no disability – to 1 (equivalent to death). We assume a toxicity 
of the intervention that results in a disability weight of 0.25 for the 6 month period of the 
intervention, but that there is no increased mortality risk. A weight of 0.25 is approximately 
that estimated for severe diarrhoea, acute low back pain, or acute gout, for example (35). A 
disability weight due to living with diagnosed HIV is taken as 0.1 (36). This is removed in 
those with ongoing ART-free viral suppression success.  
 
The cost-effectiveness threshold for a country represents the opportunity costs of resources 
required to fund the intervention, in terms of the health gains those resources could generate 
if used for alternative purposes in the public health care system (37). As such, the threshold 
for a country is not readily apparent, but $500 per DALY averted is likely to be at the upper 
end based on the magnitude of benefit if resources were spent on other programmatic 
priorities such as eliminating coverage gaps for ART if these are large (38), reflecting 
competing calls on HIV and non-HIV health care resources.  This is just over half of gross 
domestic product per capita (39).  DALYS, life years and costs were discounted from 2014 
values at 3% per annum.  The ART-free viral suppression intervention is considered cost–
saving (or “dominant”) if it results in fewer DALYs and lower cost, and cost-effective if it 
results in fewer DALYs and increased costs, but the cost per DALY averted is below $500.   
 
 
 at U
niversity of Y
ork on A
pril 12, 2016
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
9 
Results  
 
The characteristics of the simulated population of Zimbabwe in 2014 and 2020 are shown in 
Table 2.  Given assumptions that rates of testing will increase at a moderate rate  and that 
ART initiation will be at CD4 count 500 cells/mm
3
 and with adoption of option B+ for 
pregnant women, the proportion of people with HIV who are diagnosed, and the number of 
people on ART is projected to increase. As a result of these assumptions, approximately 
300,000 individuals between age of 15 and 65 are projected to be both eligible for, and have 
access to, the ART-free viral suppression intervention in 2022 (26% of the entire HIV-
positive adult population in the country at that time).  
 
The proportion of people who will receive the ART-free viral suppression intervention is 
expected to rise to 65% in 2042 (Supplementary Figure 2(a)). The number of people with on-
going ART-free viral suppression (Supplementary Figure 2 (b)) is projected to approach a 
maximum of 550,000 by the early 2030s.  The incidence of ART-free viral suppression 
failure (viral rebound) is highest soon after the AVFS program is launched as large numbers 
of people will access the therapy when it first becomes available and most failures occur 
early (Supplementary Figure 2 (c)).  
 
HIV incidence is projected to decline with or without the ART-free viral suppression 
intervention (due to enduring effects of earlier reductions in condomless sex in the mid 1990s 
and effects of viral suppression with ART), but is projected to be somewhat lower with the 
ART-free viral suppression intervention (Supplementary Figure 2 (d)). Likewise, prevalence 
of HIV (where people with on-going ART-free viral suppression success remain classified as 
being HIV positive), is projected to decline regardless of introduction of the ART-free viral 
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suppression intervention, but slightly more rapidly with the ART-free viral suppression 
intervention (Supplementary Figure 2 (e)). The number on ART will decline to below 
700,000 by 2042 without the ART-free viral suppression intervention, and to be below 
400,000 if the ART-free viral suppression intervention is introduced (Supplementary Figure 2 
(f)).  The overall proportion of people with HIV who have viral load unsuppressed (> 500 
copies/mL) is projected to decline only slowly from the level of 40% in 2022 without the 
ART-free viral suppression intervention, but to decline to close to 25% with introduction of 
the ART-free viral suppression intervention (Supplementary Figure 2 (g)). The death rate in 
people with HIV is projected to be lower with the ART-free viral suppression intervention by 
around 0.5 per 100 person years (8.4% lower; Supplementary Figure 2 (h)).  DALYs 
(discounted) will be slightly lower with the ART-free viral suppression intervention 
(Supplementary Figure 2 (i)).   Costs are higher with the ART-free viral suppression 
intervention in the initial few years of introduction due to the costs of the ART-free viral 
suppression intervention but thereafter costs are lower, due largely to less people being on 
ART (Supplementary Figure 2 (j)).  Further outputs are shown in Supplementary Figure 2(k) 
onwards. 
 
With regard to projected costs, the main differences between the scenario with and without an 
ART-free viral suppression intervention are the cost of ART, the cost of the ART-free viral 
suppression intervention, the cost of clinic visits (less expensive in people with ART-free 
viral suppression), and the cost of viral load tests (since these are done more frequently in 
people with ART-free viral suppression) (Figure 1). The ART-free viral suppression 
intervention results in 539,738 DALYs being averted (252,215 life years gained) which 
equates to an average 2.6% reduction in death rate in the whole population age 15-65 (Table 
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3). The ART-free viral suppression intervention also results in a reduction in costs of $298m 
(discounted), which represents an 8.7% reduction in the total budget over that period.  
    
We also explored the effect of variations in assumptions on the DALYs averted with the 
ART-free viral suppression intervention (Supplementary Figure 3).  Assumptions about the 
degree to which ART is expected to be durably successful affect the magnitude of benefit of 
the ART-free viral suppression intervention. In particular, when we assume a higher rate of 
interruption of ART (such that only 63% of ART experienced people have viral load < 500 
cps/mL, compared with 73% in the base case), the intervention benefit is greater. The benefit 
of the ART-free viral suppression intervention is also greater if we assume that the rate ratio 
compared with the HIV negative population for non-AIDS mortality in people in people with 
ART-free viral suppression success is 1.0, but higher (at 1.3 fold or 1.7 fold) for people with 
viral suppression on ART. If the disability weight from ART toxicity is assumed to be 0.15 
rather than 0.05 then the impact of the ART-free viral suppression intervention is again 
greater.     
 
Figure 2 presents the cost-effectiveness of the ART-free viral suppression intervention 
according to variation in combinations of key uncertain parameters of ART-free viral 
suppression efficacy and access, and cost parameters. The most strongly influential of these 
factors for cost-effectiv ness is the cost of the ART-free viral suppression intervention, with 
the efficacy of the intervention (degree of reduction in the viral rebound rate from the initial 
rate of 0.05 per year) also influential. In the context of the base case the threshold cost of the 
ART-free viral suppression intervention to be cost-effective is $1400, and the threshold to be 
cost-saving is $975. If the ART-free viral suppression intervention efficacy is lower, such 
that the % reduction in viral rebound rate / year is instead 20%, then the threshold cost of the 
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ART-free viral suppression intervention to be cost-effective is $1000 and the threshold cost 
to be cost saving is $700.  
 
Discussion 
In this modelling and economic evaluation we have assessed what properties an intervention 
aimed at HIV “cure” should have in order for it to represent a cost effective option in low 
resource settings.  The key determinants of the cost effectiveness / impact of an AVFS 
intervention are the efficacy of the intervention (as defined by the rate of rebound over time) 
and the cost of the intervention.  With the efficacy assumed in our base case, the ART-free 
viral suppression intervention would need to cost below $1400 in order to be cost-effective.   
The predicted benefits of an ART-free viral suppression intervention depend on our predicted 
outcomes of ART.   It is difficult to be certain about long-term outcomes of ART when potent 
regimens have been in use for less than 20 years, and for little over 12 years in southern 
Africa. However, data on levels of viral suppression from sub-Saharan Africa indicate that 
therapy is highly effective (29, 40-43). Long-term rates of virologic rebound in high-income 
settings have shown low and decreasing rates of viral rebound over time (28, 44). Our 
sensitivity analyses suggest that if our model proves to be overly optimistic regarding ART 
efficacy - which is plausible given experiences in high-income countries - then then more 
expensive ART-free viral suppression interventions would become cost-effective and cost-
saving. 
The costs associated with adopting the ART-free viral suppression intervention are highest 
soon after introduction due to the cost of the intervention itself and the increased intensity of 
viral load monitoring required in the initial period after the interruption. Without such 
frequent monitoring - 3 monthly for 5 years - a significant proportion of people could 
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experience a sustained period of high level viraemia (higher than that in people with viral 
breakthrough on ART). Over the longer term within our 20 year time horizon (to 2042) the 
ART-free viral suppression intervention is associated with lower costs than continued ART.  
 
The intention of this evaluation is to provide one source of guidance as research into potential 
ART-free viral suppression interventions moves forward. The potential impact of an HIV 
vaccine has been evaluated in such a way previously (23, 45). In addition, modelling and 
cost-effectiveness analyses have been used to identify the attributes of different types of cure 
approaches required to be cost-effective (46).  Specific cure strategies that were considered 
included gene therapy, chemotherapy, and stem cell transplantation.   There are many 
similarities in the approach used with our own, with the use of individual-based simulation 
models which consider possible relapse rates and the consequences.  The main differences 
concern our focus on sub-Saharan Africa rather than high income settings, with substantial 
implications for the cost of cure regimens that might be cost-effective, and our inclusion via a 
dynamic transmission model of effects on HIV incidence.   
In building our model of the ART-free viral suppression intervention we have not explicitly 
distinguished between an intervention that results in HIV eradication and one that results in 
sustained immune control of HIV. In the latter situation, advantages might be that viral 
rebound, if it occurs, would be less dramatic, and that there may be protection from super-
infection. A theoretical potential disadvantage is that due to presence of low levels of virus 
there may remain persistent immune activation and less restoration of health.   
A potential additional benefit of an ART-free viral suppression intervention that we did not 
include is that the availability of a “cure” may give an added impetus to ART programmes 
and lead to higher levels of HIV testing and greater engagement with, and adherence to, ART 
if there is the prospect of access to the intervention.  
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Our work has the limitation that we naturally have had to make a number of assumptions. 
The success of prevention efforts and future HIV incidence are uncertain, although the impact 
of the ART-free viral suppression intervention is not highly sensitive to these factors. The 
greatest uncertainties of the impact of the ART-free viral suppression intervention relate to 
the properties of that intervention and, to a lesser extent, the future effects of ART.  In 
addition, we considered a time scale of 20 years and the impact of the intervention would be 
expected to become greater with time, after a large initial investment.  In addition, we 
assumed that third line regimens are not available when in fact small numbers of people in 
Zimbabwe are on third line regimens.  We also assumed that pre-exposure prophylaxis would 
not be available when it is likely to be used in future to some extent.   
In conclusion, a new ART-free viral suppression intervention has the potential to avert 
DALYs and result in substantial cost savings in HIV care. However, the intervention will 
need to meet a stringent set of specifications in order for this to be the case. The cure field 
can utilize models such as this to better define its product development and delivery system 
imperatives.  
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Table 1. Illustration of the modelled effect of ART.  Model outputs of status in 2025 and 
2035 for people starting ART in 2015. These outputs reflect model assumptions regarding 
multiple aspects, including adherence patterns, resistance acquisition, effect of adherence and 
resistance on virologic outcome and CD4 count changes, the rate of interruption of ART and 
of ART toxicity*.  
 
Outcome Model outputs of status at 10 and 20 years 
from start of ART for people starting 
ART in 2015                       
 10 years from start 
of ART (i.e. in 
2025) 
20 years from start 
of ART (i.e. in 
2035) 
On ART with viral load < 1000 copies/mL 
 
53% 31% 
On ART with viral load > 1000 copies/mL 6% 3% 
Alive but off ART 9%  5% 
Dead from HIV disease 20% 40% 
Of those alive on ART, percentage 
experiencing an ART toxicity 
37% 34% 
Of those alive on ART, percentage on 
second-line ART 
24% 37% 
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Of those alive on ART, percentage with 
NNRTI drug resistance 
44% 56% 
Of those alive on ART, percentage with 
resistance to NNRTI, NRTI and PI classes 
1% 2% 
 
* Full details of modelling of effect of ART are given in Supplementary Material.  Also see 
supplementary material for details and comparison of outputs for adherence, virologic 
outcome, NNRTI resistance, ART discontinuation (20-29) See also references 20-23 for 
additional details.
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Table 2. Characteristics of the simulated population of Zimbabwe in 2014 and 2020 
 
Output 
 
2014 2020 Observed data 
    
Population size age 15-65 7,971,000 8,946,000 8,000,000
&
 
Number tested for HIV (per 3 
months) 
687,000 882,000 2,274,328 age 15-49 
tested in 2013* 
Proportion of men circumcised 
(age 15-65) 
0.27 0.46 0.26 in men age 15-
29 in 2014
^
 
Incidence of HIV (per 100 person 
years) age 15-65 
0.99 0.61 0.98 in 2013*  
Prevalence of HIV age 15-49 0.14 0.11 0.15 in 2011 DHS** 
Number living with HIV 1,167,000 1,124,000  
Of people with HIV, proportion 
diagnosed 
0.84 0.91  
Number on ART (age 15-65) 678,000 801,000 ~700,000 on 1
st
 Jan 
2015*** 
Of people diagnosed with HIV, 
proportion ever started ART 
0.75 0.87  
Of people with HIV, proportion 0.58 0.78  
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on ART 
Death rate (per 100 person years) 
in whole adult population age 15-
65 
1.81 1.57 1.15 age 15-49** 
Death rate (per 100 person years) 
in people with HIV age 15-65 
5.45 4.54  
Death rate (per 100 person years) 
in people on ART age 15-65 
4.13 3.20  
Of people on ART, proportion 
with VL below 500 copies/mL 
0.81 0.84 0.78 
+
 
Of people who ever started ART, 
proportion who have started 2nd 
line 
0.05 0.19 < 0.02*** 
Of people with HIV, proportion 
with VL above 500 copies/mL 
0.52 0.39  
Of people who ever started ART, 
proportion who have failed first 
line 
0.13 0.24  
 
&
 CIA World Factbook 2015 (https://www.cia.gov/library/publications/the-world-
factbook/geos/zi.html).   
* UNAIDS. Global AIDS Response Country Progress Report. Zimbabwe 2014.  ^ Data from 
PSI, Zimbabwe (personal communication).  ** Zimbabwe National Statistics Agency 
(ZIMSTAT) and ICF International. 2012. Zimbabwe Demographic and Health Survey 2010-
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11. Calverton, Maryland: ZIMSTAT and ICF International Inc.  *** personal communication 
J Murungu MoHCC. + baseline results SAPPH-IRe trial;  
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Table 3. Discounted DALYs and costs over 20 years (2022-2042) with and without ART-
free viral suppression intervention. Base case.  
 
ART-free viral  No ART-free viral  
suppression   suppression  
intervention  intervention  
----------------------------------------------------------------------------------------------------------------
----------------- 
DALYs     46,610,496   47,150,234 
         
DALYs averted    539,738   ---- 
compared with no ART-free  
viral suppression 
intervention 
 
Costs (in $m)*   $3,139    $3,437 
 
Increment in costs (in $m)  -$298    ---- 
compared with no ART-free  
viral suppression 
intervention      
----------------------------------------------------------------------------------------------------------------
----------------- 
* 8.7% reduction in costs with ART-free viral suppression intervention  
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Figure Legends 
 
Figure 1. Overall programme costs in ($m over 20 years from 2022-2042) according to 
whether the 
ART-free viral suppression (AFVS) intervention is introduced or not (discounted at 3%  per 
annum from 2015 )  
 
Figure 2. Results of multi-way sensitivity analysis showing the effects of (i) efficacy and 
access of the ART-free viral suppression (AFVS) intervention and (ii) unit costs, on the cost 
effectiveness and level of cost saving. In the context of the base case, highlighted, (% of 
people with access = 90%, % reduction in viral rebound rate / year = 50%, cost of viral load 
$22, cost of visits during ART-free viral suppression success $10), the threshold cost of the 
ART-free viral suppression intervention to be cost-effective = $1400, and the threshold to be 
cost-saving = $975. 
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Overall programme costs in ($m over 20 years from 2022-2042) according to whether the 
ART-free viral suppression (AFVS) intervention is introduced or not (discounted at 3%  per annum from 2015 )  
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